Oncopeptides AB (ONCO) NPV
0.026 SEK
(1.69%)
- Add to watchlist
- This stock can be held in a
0.026 SEK
(1.69%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.026 SEK
(1.69%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Contact details
Important dates
General stock information
- Short code:
- ONCO
- ISIN:
- SE0009414576
- Market cap:
- 139.10 million SEK
- Shares in issue:
- 211.26 million
- Sector:
- Biotechnology
- Exchange:
- Stockholm Stock Exchange
- Country:
- Sweden
- Currency:
- Swedish Krona
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.